The Women’s Health Initiative: What Happened, What It Broke, and Where Do We as Doctors & Patients Go From Here?

There was a moment in modern medicine that changed the trajectory of women’s health for more than two decades.

It was 2002. I was in my office seeing patients with my other ObGyn colleagues.

I remember that day viscerally. In the field of Women’s Health, everything changed that day.

The Women’s Health Initiative (WHI) trial was halted early. Headlines exploded overnight:

“Hormones Cause Breast Cancer.” “Hormone Therapy Is Dangerous.” “Women Should Stop HRT Immediately.”

Millions of women were taken off hormones almost instantly.

Physicians panicked. Patients panicked. And menopause care, as a field, retreated.

What followed was not just confusion.

It was a generation of women left untreated.

And a generation of doctors inadequately trained.

Let’s talk about what actually happened.

What the WHI Studied and What It Didn’t

The Women’s Health Initiative was a large, randomized controlled trial designed to evaluate whether hormone therapy prevented chronic disease in postmenopausal women.

But here are critical details that were lost in media translation:

• The average age of participants was 63 years old.
• Many were more than 10 years past menopause.
• The study used oral conjugated equine estrogen (Premarin) and medroxyprogesterone acetate (Provera) — the estrogen came from a Pregnant Mare’s urine. I ask you, what do women have in common with a pregnant horse? The answer is absolutely nothing. The progesterone’s biochemical structure didn’t even resemble the natural progesterone produced by women’s bodies.
• The formulations were not identical to the bioidentical estriol, estradiol, and progesterone used today.
• The primary goal was disease prevention, not symptom relief.

The initial publication showed:

• A small increased relative risk of breast cancer in the estrogen + progestin group.
• Increased risk of blood clots and stroke in older participants.
• Cardiovascular risks when therapy was started late after menopause.

The nuance was complicated.

The headlines were not.

The Damage of Simplification

Within months:

• Hormone prescriptions dropped by nearly 50%.
• Physicians stopped initiating therapy.
• Women were told to “just get through it.”
• Menopause was reframed as something to endure rather than treat.

But what was not emphasized was this:

The absolute risk increase in breast cancer was small – approximately 8 additional cases per 10,000 women per year in the combined therapy group. And mind you, the combined therapy was using hormones that our human bodies don’t actually recognize.

Later analyses revealed something even more important:

Age and timing matter.

The Reversal: What We Know Now

Subsequent re-analyses of WHI data, along with newer research, clarified several critical points:

1. The “Timing Hypothesis.”

   Women who initiate hormone therapy within 10 years of menopause or before age 60 have:

   • Lower cardiovascular risk
   • Potential cardiovascular benefit in some groups
   • Lower overall mortality in certain analyses

   This differs dramatically from initiating hormones at age 63+.

2. Estrogen Alone vs. Combined Therapy

   In women who had a hysterectomy and took estrogen alone:

   • No increased breast cancer risk was seen in early data.
   • Long-term follow-up suggested a possible reduction in breast cancer incidence in some groups.

   The risk profile was not identical across therapies.

3. Route and Formulation Matter

   Oral estrogen increases clotting risk more than transdermal estrogen.

   Micronized progesterone may have a different breast and cardiovascular risk profile than synthetic progestins.

   These distinctions were not widely understood in 2002.

The Long Shadow on Medical Training

Here is the uncomfortable truth:

Many physicians practicing today were trained in the post-WHI fear era.

Education on menopause in medical school and residency has historically been minimal. A 2018 survey published in Menopause found that:

• Over 80% of OB/GYN residents felt inadequately prepared to manage menopause.
• Even fewer internal medicine physicians reported formal menopause training.

So what happened?

Doctors were taught:

• Use the lowest dose for the shortest time.
• Avoid hormones unless absolutely necessary.
• Focus on SSRIs (antidepressants) and lifestyle changes.
• The symptoms of menopause are just a part of life and there may not be any good solutions

And that became the default narrative.

Millions of women suffered through menopause in silence.

But medicine evolves.

The data evolved.

Unfortunately, many training programs did not.

The Cost to Women

What did this 20-year retreat from hormone therapy cost?

• Untreated vasomotor symptoms (disruptive hot flashes and night sweats)
• Severe sleep disruption
• Increased osteoporosis risk
• Earlier bone loss
• Sexual pain and genitourinary syndrome of menopause
• Reduced quality of life
• Workplace productivity loss
• Depression and anxiety rampant amongst menopausal women
• Relationship disruptions

A 2023 Mayo Clinic study estimated that menopause-related symptoms cost U.S. businesses billions annually in lost productivity. Not to mention the personal impact on people. Women. Human beings.

This is not a minor inconvenience.

This is public health.

My Experience as a Physician

I practiced in the shadows of WHI.

I watched colleagues stop prescribing hormones almost overnight.

I watched women suffer quietly – told it was “natural,” and they should endure it.

But menopause is natural.

Suffering unnecessarily is not.

As I deepened my work in longevity and functional medicine, I began re-evaluating the literature myself. Not the headlines. The actual data.

And what I saw was this:

The story was never black and white.

It was about:

• Timing
• Patient selection
• Formulation of the hormones themselves
• Risk stratification
• Individualization

Medicine should not be driven by fear.

It should be driven by evidence. And by compassion and understanding.

Why Some Doctors Still Practice Fear-Based Medicine

That sounds harsh.

But it is not about intelligence.

It is about exposure and training.

If a physician:

• Has not pursued updated menopause education
• Is relying on 2002-era interpretations
• Is uncomfortable discussing risk nuance
• Has a high-volume practice with limited time

Hormone therapy may feel intimidating.

So it is avoided.

Women are told: “You’re fine.” “It’s just aging.” “Try meditation.”

“Perhaps you’re depressed.”

Meditation is valuable. No question about it. So is exercise, healthy eating, hydration, and stress management.

But none of these lifestyle measures replace estradiol in a severely estrogen-deficient brain, or Progesterone, Testosterone, DHEA, and other vital hormones.

The Balanced View

Hormone therapy is not for everyone.

It is contraindicated in certain cases:

• Active breast cancer
• Certain clotting disorders
• Active liver disease

Risk assessment matters.

Family history matters.

Personal history matters.

But blanket avoidance is not evidence-based.

Blanket fear is not medicine.

Where We Are Now

Major organizations, including:

• The North American Menopause Society (now The Menopause Society)
• The American College of Obstetricians and Gynecologists
• The Endocrine Society

Now state clearly:

For healthy women under 60 or within 10 years of menopause onset, hormone therapy is a safe and effective treatment for bothersome menopausal symptoms when appropriately prescribed.

That is not fringe medicine.

That is the consensus.

What Women Deserve

Women deserve:

• Physicians trained in updated menopause science
• Individualized risk discussions
• Nuanced conversations about breast cancer risk
• Understanding of transdermal vs. oral options
• Recognition that quality of life matters

Menopause is not a weakness.

It is a hormonal transition. It is a biological event in a woman’s body that deserves care, consideration, and collaboration.

And hormonal transitions deserve hormonal literacy.